Chee Wah Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2316393/publications.pdf

Version: 2024-02-01

40 papers

4,563 citations

279798 23 h-index 265206 42 g-index

48 all docs 48 docs citations

48 times ranked

9751 citing authors

#	Article	IF	CITATIONS
1	A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nature Biotechnology, 2020, 38, 1073-1078.	17.5	1,042
2	Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients. Cell Reports, 2021, 34, 108728.	6.4	568
3	Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe, The, 2021, 2, e240-e249.	7.3	322
4	Evidence for SARS-CoV-2 related coronaviruses circulating in bats and pangolins in Southeast Asia. Nature Communications, 2021, 12, 972.	12.8	276
5	Dampened NLRP3-mediated inflammation in bats and implications for a special viral reservoir host. Nature Microbiology, 2019, 4, 789-799.	13.3	245
6	Discovery and Genomic Characterization of a 382-Nucleotide Deletion in ORF7b and ORF8 during the Early Evolution of SARS-CoV-2. MBio, 2020, 11 , .	4.1	245
7	Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. Clinical Microbiology and Infection, 2022, 28, 612.e1-612.e7.	6.0	231
8	Connecting clusters of COVID-19: an epidemiological and serological investigation. Lancet Infectious Diseases, The, 2020, 20, 809-815.	9.1	229
9	Enterovirus 71 Uses Cell Surface Heparan Sulfate Glycosaminoglycan as an Attachment Receptor. Journal of Virology, 2013, 87, 611-620.	3.4	183
10	Viral Dynamics and Immune Correlates of Coronavirus Disease 2019 (COVID-19) Severity. Clinical Infectious Diseases, 2021, 73, e2932-e2942.	5.8	143
11	Characterization of a filovirus (MÄ>nglà virus) from Rousettus bats in China. Nature Microbiology, 2019, 4, 390-395.	13.3	116
12	Infection of human Nasal Epithelial Cells with SARS-CoV-2 and a 382-nt deletion isolate lacking ORF8 reveals similar viral kinetics and host transcriptional profiles. PLoS Pathogens, 2020, 16, e1009130.	4.7	98
13	Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2. Emerging Microbes and Infections, 2020, 9, 900-902.	6.5	89
14	Serological differentiation between COVID-19 and SARS infections. Emerging Microbes and Infections, 2020, 9, 1497-1505.	6.5	89
15	Polysulfonate suramin inhibits Zika virus infection. Antiviral Research, 2017, 143, 186-194.	4.1	67
16	SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness. Scientific Reports, 2021, 11, 2062.	3.3	58
17	WHO international standard for SARS-CoV-2 antibodies to determine markers of protection. Lancet Microbe, The, 2022, 3, e81-e82.	7.3	56
18	VP1 residues around the five-fold axis of enterovirus A71 mediate heparan sulfate interaction. Virology, 2017, 501, 79-87.	2.4	51

#	Article	IF	CITATIONS
19	Inhibition of Enterovirus 71 (EV-71) Infections by a Novel Antiviral Peptide Derived from EV-71 Capsid Protein VP1. PLoS ONE, 2012, 7, e34589.	2.5	41
20	Decreased memory B cell frequencies in COVIDâ€19 delta variant vaccine breakthrough infection. EMBO Molecular Medicine, 2022, 14, e15227.	6.9	31
21	Cell surface $\hat{l}\pm 2,3$ -linked sialic acid facilitates Zika virus internalization. Emerging Microbes and Infections, 2019, 8, 426-437.	6.5	29
22	Neutralizing Activity and SARS-CoV-2 Vaccine mRNA Persistence in Serum and Breastmilk After BNT162b2 Vaccination in Lactating Women. Frontiers in Immunology, 2021, 12, 783975.	4.8	29
23	Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool. PLoS ONE, 2016, 11, e0162771.	2.5	27
24	Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial. Clinical Infectious Diseases, 2022, 75, 2088-2096.	5.8	23
25	Electrostatic interactions at the five-fold axis alter heparin-binding phenotype and drive enterovirus A71 virulence in mice. PLoS Pathogens, 2019, 15, e1007863.	4.7	22
26	Early detection of neutralizing antibodies against SARS-CoV-2 in COVID-19 patients in Thailand. PLoS ONE, 2021, 16, e0246864.	2.5	20
27	Low postpandemic wave SARSâ€CoVâ€2 seroprevalence in Kuala Lumpur and Selangor, Malaysia. Journal of Medical Virology, 2021, 93, 647-648.	5.0	19
28	Immune responses against enterovirus A71 infection: Implications for vaccine success. Reviews in Medical Virology, 2019, 29, e2073.	8.3	18
29	Serological evidence of human infection by bat orthoreovirus in Singapore. Journal of Medical Virology, 2019, 91, 707-710.	5.0	18
30	Dynamics of Neutralizing Antibody and T-Cell Responses to SARS-CoV-2 and Variants of Concern after Primary Immunization with CoronaVac and Booster with $BNT162b2$ or $ChAdOx1$ in Health Care Workers. Vaccines, 2022, 10, 639.	4.4	18
31	Bat virome research: the past, the present and the future. Current Opinion in Virology, 2021, 49, 68-80.	5.4	17
32	Inhibition of enterovirus 71 infection by antisense octaguanidinium dendrimer-conjugated morpholino oligomers. Antiviral Research, 2014, 107, 35-41.	4.1	14
33	Human Nasal Epithelial Cells Sustain Persistent SARS-CoV-2 Infection <i>In Vitro</i> , despite Eliciting a Prolonged Antiviral Response. MBio, 2022, 13, e0343621.	4.1	12
34	Identification of ZDHHC17 as a Potential Drug Target for Swine Acute Diarrhea Syndrome Coronavirus Infection. MBio, 2021, 12, e0234221.	4.1	11
35	Serological evidence and experimental infection of cynomolgus macaques with pteropine orthoreovirus reveal monkeys as potential hosts for transmission to humans. Emerging Microbes and Infections, 2019, 8, 787-795.	6.5	8
36	An unusual COVID-19 case with over four months of viral shedding in the presence of low neutralizing antibodies: a case report. Journal of Biomedical Research, 2020, 34, 470.	1.6	8

#	Article	IF	CITATIONS
37	Vaccine candidates generated by codon and codon pair deoptimization of enterovirus A71 protect against lethal challenge in mice. Vaccine, 2021, 39, 1708-1720.	3.8	7
38	Serological Cross Reactivity between Zika and Dengue Viruses in Experimentally Infected Monkeys. Virologica Sinica, 2018, 33, 378-381.	3.0	4
39	Identification and characterization of neutralization epitopes at VP2 and VP1 of enterovirus A71. Journal of Medical Virology, 2018, 90, 1164-1167.	5.0	3
40	Enterovirus 71 receptors: promising drug targets?. Expert Review of Anti-Infective Therapy, 2013, 11, 547-549.	4.4	2